SGIOF SHIONOGI & CO
- 46.560
- 0.0000.00%
SHIONOGI & CO News
FunPep - 1Q concludes an option agreement with Shionogi Pharmaceutical regarding the antibody-inducing peptide “FPP004X”
FunPep ＜4881＞ announced consolidated financial results for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 13th. Sales increased 54.8% from the same period last year to 50 billion yen, operating loss was 183 million yen (loss of 378 million yen in the same period last year), ordinary loss was 170 million yen (loss of 343 million yen), and quarterly net loss attributable to parent company shareholders was 168 million yen (341 million yen). About the antibody-inducing peptide project, the antibody-inducing peptide “FPP003” (label
Shionogi & Co FY Net Y162.03B Vs Net Y184.97B
Shionogi & Co. Ltd. (4507.TO) Osaka Year Ended March 31 GROUP 2024 2023 Revenue Y435.08 bln Y426.68 bln Operating Profit Y153.31 bln Y14
Akili Amends Strategic Distribution Agreement With Shionogi & Co. >AKLI
Akili Amends Strategic Distribution Agreement With Shionogi & Co. >AKLI
Shionogi & Co Raises FY Dividend Plan to Y160.00
Shionogi & Co. Ltd. (4507.TO) PARENT Latest Revision Previous For Year to Mar 2024 Plan Year-end Y85.00 Y75.00 Annual Y160.00 Y1
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares
Shionogi & Co (TYO:4507) has completed the cancellation of 10.84 million treasury shares, equivalent to 3.53% of total outstanding shares before the cancellation, on April 17, according to its filing
FunPep --- signed an option agreement with Shionogi Pharmaceutical, increasing sales potential of tens of billion yen domestically alone
FunPep ＜4881＞ is a biotechnology venture established in 2013 for the purpose of putting the research results of functional peptides into practical use at Osaka University Graduate School of Medicine. We are working on the development of pharmaceuticals to replace expensive antibody pharmaceuticals using antibody-inducing peptide technology based on functional peptides developed independently. Also, in 2022/10, Anti-Aging Peptide Co., Ltd. (currently FunPep Health Care Co., Ltd.) became a subsidiary for cosmetics and other products other than pharmaceuticals
Express News | Akili Shares Are Trading Higher After the Company Announced That Its Japanese Partner, Shionogi & Co. Ltd, Has Submitted Akili's Digital Therapeutic SDT-001 for Marketing Approval With the Ministry of Health, Labor, and Welfare
Shionogi & Co. GAAP EPS of ¥435.74, Revenue of ¥336.82B
Shionogi & Co. 3Q Net Profit Y36.6B Beat Y33.34B Expected in Poll of Analysts by FactSet >4507.TO
Shionogi & Co. 3Q Net Profit Y36.6B Beat Y33.34B Expected in Poll of Analysts by FactSet >4507.TO
Shionogi & Co Sees FY Net Y155.00B
Shionogi & Co. Ltd. also released the following forecasts: GROUP Year Ending Mar 2024 Revenue Y450.00 bln Operating Profit Y150.00 bln Pretax Profit
Shionogi & Co Buys Back 1.23 Million Shares in November
Shionogi & Co (TYO:4507) has repurchased 1.23 million shares for 8.65 billion yen from Nov. 1 to Nov. 30, according to its filing on Monday. The pharmaceutical company said it could repurchase up to 1
Shionogi & Co 1H Net Y90.59B Vs Net Y57.26B
Shionogi & Co. Ltd. (4507.TO) Osaka 1st Half Ended September 30 GROUP 2023 2022 Revenue Y230.54 bln Y150.78 bln Operating Profit Y98.11 bl
GSK Unit ViiV Raises Outlook on Long-term HIV Therapies
Shionogi & Co. GAAP EPS of ¥144.57, Revenue of ¥109.31B
Shionogi & Co Sees 1H Net Y78.00B
Shionogi & Co. Ltd. also released the following forecasts: GROUP 1st Half To Sep 2023 Revenue Y450.00 bln Operating Profit Y80.50 bln Pretax Profit
Shionogi & Co 1Q Net Y42.56B Vs Net Y34.72B
Shionogi & Co. Ltd. (4507.TO) Osaka 1st Quarter Ended June 30 GROUP 2023 2023 Revenue Y109.31 bln Y71.84 bln Operating Profit Y46.59 bln
GSK Announces EU Nod for HIV Prevention Therapy
Analysis
Price Target
No Data
